In a bid to advance the development of an RNAi-based treatment for Huntington's disease, Sirna Therapeutics announced this week that it has formed a collaboration with gene therapy firm Targeted Genetics.

Through the deal, Sirna will be able to apply Targeted Genetics adeno-associated virus vector-based delivery technology to its own siRNA-based drug candidates in order to overcome the challenges of delivery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.